CRHM's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.64 -- higher than just 5.92% of US-listed equities with positive expected earnings growth.
Of note is the ratio of CRH Medical Corp's sales and general administrative expense to its total operating expenses; 88.08% of US stocks have a lower such ratio.
The ratio of debt to operating expenses for CRH Medical Corp is higher than it is for about 90.39% of US stocks.
Stocks with similar financial metrics, market capitalization, and price volatility to CRH Medical Corp are MSGN, CHCI, MTA, CG, and GRIL.
CRH Medical Corporation Common Shares of Beneficial Interest (CRHM) Company Bio
CRH Medical Corporation, a medical company, provides products and services to physicians for the treatment of gastrointestinal diseases in the United States. The company was founded in 2000 and is based in Vancouver, Canada.
Greystone Capital recently released its Q4 2020 Investor Letter, a copy of which you can download here. Greystone is a privately held investment company. The investment firm seeks to simplify and add value by identifying opportunities in good and bad markets. During the fourth quarter of 2020, returns for separate accounts managed by Greystone Capital […]
New NCCN Guidelines for Patients: Survivorship series provides expert advice to help cancer survivors sustain better health while monitoring for any long-term side effects or recurrences.SURVIVOR TV show winner and cancer survivor, Ethan Zohn shares what cancer survivorship means to him.
CRH Medical Corporation ("CRH", or the "Company") (TSX: CRH) (NYSE MKT: CRHM) announces that it has received notice today that its largest customer, United Digestive ("UD"), does not intend to renew its professional services agreements pursuant to which CRH provides anesthesia services to 12 of UD's surgery centers in the Greater Atlanta Georgia market. UD represents a significant portion of CRH's revenue, and is expected to represent approximately 20% of adjusted operating shareholder EBITDA ("EBITDA") in 2021. The current professional services agreements are scheduled to expire on October 31, 2021, meaning that the non-renewal will become effective sometime thereafter, such that the effect on CRH's financial results will be seen beginning in 2022.